Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus

Objective The management of systemic lupus erythematosus (SLE) flares can incur substantial healthcare costs. In the phase III BLISS-SC trial, subcutaneous (SC) belimumab 200 mg plus standard therapy was associated with significant reductions in time to severe flare, and risk of flares, versus place...

Full description

Bibliographic Details
Main Authors: Tasneem Lokhandwala, Binglin Yue, Anna D Coutinho
Format: Article
Language:English
Published: BMJ Publishing Group 2021-09-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/8/1/e000438.full